AVDL

Avadel Pharmaceuticals plc - Ordinary Share (AVDL)

About Avadel Pharmaceuticals plc - Ordinary Share (AVDL)

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

Details

Daily high

$9.57

Daily low

$9.07

Price at open

$9.17

52 Week High

$17.30

52 Week Low

$6.38

Market cap

888.1M

Dividend yield

0.00%

Volume

1.5M

Avg. volume

1.8M

P/E ratio

-33.47

Avadel Pharmaceuticals plc - Ordinary Share News